title: High prevalence of normal serum albumin in NASH patients with ascites: a retrospective analysis.
abstract: BACKGROUND
  Ascites usually occurs in the setting of end-stage liver disease and low serum albumin and is associated with increased mortality. However, some patients develop ascites despite normal serum albumin (NSA), when a higher portal pressure and/or enhanced renal sodium retention would be expected. This study investigated the relationship between the hepatic venous pressure gradient (HVPG) and serum albumin in ascitic patients with different etiologies of cirrhosis and mortality.
  
  
  METHODS
  Records of all patients with non-malignant ascites who underwent HVPG measurement from 2005 to 2009 were reviewed.
  
  
  RESULTS
  One hundred and thirty-eight 138 patients met inclusion criteria; 18.8% had NSA. No difference in sodium excretion or diuretic use was noted in patients with and without NSA. NASH patients were more likely to have a NSA (34.2% vs 12.4%; P=0.001) as well as lower HVPG (15 vs 17.9 mmHg; P=0.009) compared to other etiologies. MELD and HVPG predicted overall survival. However, mortality did not differ by disease etiology, though NASH patients had lower CTP (7.6 vs 8.5; P<0.001) and MELD (15.6 vs 18.1; P=0.09) scores, particularly among patients who died.
  
  
  CONCLUSIONS
  In patients with ascites and NSA, there were no increase in HVPG or urinary sodium retention. NASH patients with ascites had lower HVPG and a higher prevalence of NSA. They also had a higher mortality relative to MELD and CTP scores in other patients. In these patients, mechanisms other than portal and oncotic pressures and sodium retention play a role in ascites development, and increase mortality rate when complicated by low albumin.
authors.affiliation: Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. souria@upmc.edu
authors.forename: Achuthan
authors.initials: A
authors.lastname: Sourianarayanane
authors.forename: Robert S
authors.initials: RS
authors.lastname: O'Shea
authors.forename: David S
authors.initials: DS
authors.lastname: Barnes
authors.forename: Arthur J
authors.initials: AJ
authors.lastname: McCullough
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001201:Ascites / Q000209:etiology*; D015331:Cohort Studies; D005234:Fatty Liver / Q000097:blood* / Q000401:mortality; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008102:Liver Circulation / Q000502:physiology; D008103:Liver Cirrhosis / Q000097:blood* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012709:Serum Albumin / Q000032:analysis*; D012720:Severity of Illness Index; D012964:Sodium / Q000097:blood / Q000652:urine; D014690:Venous Pressure / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists; D012709:Serum Albumin; D012964:Sodium